Galderma will fund the deal through existing cash reserves and bank financing. The deal should close in the fourth quarter of 2026 or early 2027, pending regulatory sign-off and standard closing conditions. Lazard leads financial advising for Galderma, with JPMorgan also advising and Ropes & Gray providing legal counsel. Raymond James leads financial advising to ZO Skin Health and Blackstone, with Citi also advising and Weil, Gotshal & Manges and Paul Weiss handling legal matters.
what changed
Galderma now owns three major skincare brands: Cetaphil, Alastin, and ZO Skin Health. The company framed the deal as a way to compete in the medical-grade skincare segment, which it described as fast-growing. Galderma said it would spend more on commercial efforts during the first year of ownership to fuel growth starting in the second year after closing.
The company expects the deal to slightly shrink its Core EBITDA margin in 2027, then reach a margin matching the group average by 2028. Galderma projects the deal will be Core EPS neutral in the first full year after closing. This financial path suggests the company views ZO as a turnaround opportunity rather than an immediate margin booster.
Dr. Zein Obagi, the founder and medical director, will stay involved with the brand. In a statement, he said ZO Skin Health has been his life's work and that he trusts Galderma shares the company's dedication to science and its ties with healthcare professionals. Obagi emphasized that the brand's philosophy will endure and grow for the benefit of dermatologists, plastic surgeons, aestheticians, and patients.
Blackstone more than doubled ZO's revenue during its ownership period, according to Shary Moalemzadeh, a senior managing director at the firm. That growth path and the $1.5 billion price tag suggest the skincare market remains attractive to large buyers despite economic uncertainty.
what it means for practices
For medspa and aesthetic practices, the deal puts skincare distribution under a larger parent company with deeper resources. Galderma's stated plan to expand commercial spending and geographic reach could mean more aggressive marketing and sales support for ZO products. The company also signaled it would use its ties with dermatologists, plastic surgeons, and aesthetic professionals to grow the brand.
ZO's protocol-based approach works well with Alastin's peptide-based regenerative products, which focus on pre- and post-procedure care. Practices already carrying both lines may see coordinated support or bundled offerings. Practices carrying only one brand now have a parent company with reason to cross-sell the other.
Galderma's Integrated Dermatology Strategy positions it to expand ZO Skin Health through its existing network of healthcare professionals. The company sees the deal as a way to reignite growth through spending on innovation and commercial reach, suggesting that ZO's growth may have plateaued under Blackstone's ownership despite the revenue doubling.
what we don't know yet
The document does not specify whether Galderma plans to maintain ZO's current distribution model or integrate it into existing channels. It also does not detail pricing changes, which products Galderma might discontinue, or shifts in the company's clinical training programs. The timing of integration choices will likely become clearer after the deal closes in late 2026 or early 2027. Regulatory approval requirements are mentioned but not detailed.
Business information, not medical or legal advice. Verify regulatory status at FDA.gov.
